COVID-19 Convalescent Plasma Therapy

COVID-19 Convalescent Plasma Therapy

This study is an open-label trial in which hospitalized patients with risk factors of severe coronavirus disease 2019 [COVID-19] will be receive treatment with convalescent plasma (≤ 15 days from symptoms start).

Inclusion Criteria:

• 18 Years and older
• Presence of risk factors of severe COVID 19 diagnosed by quantitative polymerase chain reaction by reverse transcription (RT-qPCR)
• Patients with no more than 15 days from the onset of symptoms
• Signed informed consent

Exclusion Criteria:

• Severely ill patients admitted directly to the ICU.
• Need for mechanical ventilation at the time of hospital admission, regardless of the time of clinical evolution.
• History of previous hypersensitivity to plasma transfusions.
• History of immunoglobulin A (IgA) deficiency
• Pregnancy